Sodium hyaluronate - Lantibio

Drug Profile

Sodium hyaluronate - Lantibio

Alternative Names: Hyaluronan - TRB Chemedica; Hyaluronic acid - Lantibio; Rejena; SVS-20; Vismed®

Latest Information Update: 13 May 2014

Price : $50

At a glance

  • Originator TRB Chemedica
  • Developer Lantibio
  • Class Adjuvants; Antirheumatics; Eye disorder therapies; Glycosaminoglycans; Urologics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dry eyes

Most Recent Events

  • 13 May 2014 Discontinued - Preregistration for Dry eyes in USA (Topical)
  • 08 Apr 2011 Novartis completes acquisition of Alcon
  • 26 Aug 2010 Alcon has been acquired by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top